Acute respiratory distress syndrome (ARDS) is characterised by damage to the arteriolar-capillary endothelium and alveolar epithelium that leads to surfactant deficiency and atelectasis. Alveolar collapse and pulmonary oedema will further induce surfactant inactivation. Surfactant supplementation has been suggested but the treatment is unpredictable. Poor response may be due to inhibition of administered surfactant by plasma components filling the alveolar space, severity of lung injury, time of surfactant application and inadequate dose.We reported the course of gas exchange and pulmonary mechanics after instillation of surfactant in 14 children (3 months-7 years) with severe ARDS, defined as an OI > 30 and a PaO2/FiO2 200 for more than 12...
Since the Food and Drug Administration (FDA) approved exogenous surfactant in the early 90s for the ...
The rationale for surfactant replacement therapy in patients with acute respiratory distress syndrom...
The rationale for surfactant replacement therapy in patients with acute respiratory distress syndrom...
Acute respiratory distress syndrome (ARDS) is characterized by damage to the arteriolar-capillary en...
Abstract The acute respiratory distress syndrome (ARDS) is a frequent, life-threatening disease in w...
<p>Acute respiratory distress syndrome (ARDS) remains the primary indication for admission to paedia...
In the last decade there has been growing insight into surfactant function and metabolism and on how...
In the last decade there has been growing insight into surfactant function and metabolism and on how...
In the last decade there has been growing insight into surfactant function and metabolism and on how...
In the last decade there has been growing insight into surfactant function and metabolism and on how...
In the last decade there has been growing insight into surfactant function and metabolism and on how...
The Acute Respiratory Distress Syndrome (ARDS) is a pulmonary lesion of multifactorial cause in whic...
PubMedID: 14580923Purpose. The aim of this prospectively designed study was to investigate the effic...
In children with acute lung injury the endogenous surfactant system is altered via a variety of diff...
Since the Food and Drug Administration (FDA) approved exogenous surfactant in the early 90s for the ...
Since the Food and Drug Administration (FDA) approved exogenous surfactant in the early 90s for the ...
The rationale for surfactant replacement therapy in patients with acute respiratory distress syndrom...
The rationale for surfactant replacement therapy in patients with acute respiratory distress syndrom...
Acute respiratory distress syndrome (ARDS) is characterized by damage to the arteriolar-capillary en...
Abstract The acute respiratory distress syndrome (ARDS) is a frequent, life-threatening disease in w...
<p>Acute respiratory distress syndrome (ARDS) remains the primary indication for admission to paedia...
In the last decade there has been growing insight into surfactant function and metabolism and on how...
In the last decade there has been growing insight into surfactant function and metabolism and on how...
In the last decade there has been growing insight into surfactant function and metabolism and on how...
In the last decade there has been growing insight into surfactant function and metabolism and on how...
In the last decade there has been growing insight into surfactant function and metabolism and on how...
The Acute Respiratory Distress Syndrome (ARDS) is a pulmonary lesion of multifactorial cause in whic...
PubMedID: 14580923Purpose. The aim of this prospectively designed study was to investigate the effic...
In children with acute lung injury the endogenous surfactant system is altered via a variety of diff...
Since the Food and Drug Administration (FDA) approved exogenous surfactant in the early 90s for the ...
Since the Food and Drug Administration (FDA) approved exogenous surfactant in the early 90s for the ...
The rationale for surfactant replacement therapy in patients with acute respiratory distress syndrom...
The rationale for surfactant replacement therapy in patients with acute respiratory distress syndrom...